Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor
Обратное развитие смертельной коронавирусной инфекции у кошек под действием коронавирусного ингибитора протеазы широкого спектра действия
2016-03-30
SCID: 54.1/hujycfwq
Discuss with AI
3C-like protease inhibitorFIP virusantiviral treatmentbroad-spectrum coronavirus inhibitorfeline infectious peritonitis
Figures from the paper
Abstract (AI)
Coronaviruses infect animals and humans causing a wide range of diseases. The diversity of coronaviruses in many mammalian species is contributed by relatively high mutation and recombination rates during replication. This dynamic nature of coronaviruses may facilitate cross-species transmission and shifts in tissue or cell tropism in a host, resulting in substantial change in virulence. Feline enteric coronavirus (FECV) causes inapparent or mild enteritis in cats, but a highly fatal disease, called feline infectious peritonitis (FIP), can arise through mutation of FECV to FIP virus (FIPV). The pathogenesis of FIP is intimately associated with immune responses and involves depletion of T cells, features shared by some other coronaviruses like Severe Acute Respiratory Syndrome Coronavirus. The increasing risks of highly virulent coronavirus infections in humans or animals call for effective antiviral drugs, but no such measures are yet available. Previously, we have reported the inhibitors that target 3C-like protease (3CLpro) with broad-spectrum activity against important human and animal coronaviruses. Here, we evaluated the therapeutic efficacy of our 3CLpro inhibitor in laboratory cats with FIP. Experimental FIP is 100% fatal once certain clinical and laboratory signs become apparent. We found that antiviral treatment led to full recovery of cats when treatment was started at a stage of disease that would be otherwise fatal if left untreated. Antiviral treatment was associated with a rapid improvement in fever, ascites, lymphopenia and gross signs of illness and cats returned to normal health within 20 days or less of treatment. Significant reduction in viral titers was also observed in cats. These results indicate that continuous virus replication is required for progression of immune-mediated inflammatory disease of FIP. These findings may provide important insights into devising therapeutic strategies and selection of antiviral compounds for further development for important coronaviruses in animals and humans.
Key Findings
1
A broad-spectrum coronavirus 3C-like protease inhibitor was evaluated as therapy for experimentally induced feline infectious peritonitis (FIP).
2
Antiviral therapy significantly reduced viral titers, supporting a requirement for continuous virus replication in progression of FIP’s immune-mediated inflammatory disease.
3
The results identify 3CLpro inhibition as a promising strategy for developing antivirals against severe coronavirus infections in animals and potentially humans.
4
Treated cats rapidly improved in fever, ascites, lymphopenia, and overall illness, returning to normal health within 20 days or less.
5
Treatment produced full recovery in cats even after clinical and laboratory signs appeared at a disease stage otherwise considered 100% fatal.
Research Object
Feline infectious peritonitis (FIP) in laboratory cats caused by feline infectious peritonitis virus (FIPV)
Research Subject
Therapeutic efficacy of a broad-spectrum 3C-like coronavirus protease (3CLpro) inhibitor, including reversal of fatal disease progression, clinical recovery, and reduction of viral titers
Publication Details
Publication Date
2016-03-30
Journal
Publisher
ISSN
Cited by
238
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai9
An update on feline infectious peritonitis: Virology and immunopathogenesis2014
An update on feline infectious peritonitis: Diagnostics and therapeutics2014
Spike Protein Fusion Peptide and Feline Coronavirus Virulence2012
Mutation in Spike Protein Cleavage Site and Pathogenesis of Feline Coronavirus2013
Feline Coronavirus Serotypes 1 and 2: Seroprevalence and Association with Disease in Switzerland2005
Epidemiology of feline infectious peritonitis among cats examined at veterinary medical teaching hospitals2001
Phylogenetic Analysis of Feline Coronavirus Strains in an Epizootic Outbreak of Feline Infectious Peritonitis2013
The influence of age and genetics on natural resistance to experimentally induced feline infectious peritonitis2014
An eight-year epidemiologic study based on baculovirus-expressed type-specific spike proteins for the differentiation of type I and II feline coronavirus infections2014
Cited by5
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease2020
Diagnosis of feline infectious peritonitis: Update on evidence supporting available tests2018
Feline Infectious Peritonitis: European Advisory Board on Cat Diseases Guidelines2023
A retrospective study of clinical and laboratory features and treatment on cats highly suspected of feline infectious peritonitis in Wuhan, China2021
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal2022